Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Shanghai Pharmaceuticals Holding Co's average EBITDA Per Share Growth Rate was 21.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 2.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -2.10% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 5.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shanghai Pharmaceuticals Holding Co was 62.50% per year. The lowest was -21.50% per year. And the median was 9.35% per year.
Shanghai Pharmaceuticals Holding Co (OTCPK:SHPMF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Shanghai Pharmaceuticals Holding Co 3-Year EBITDA Growth Rate Related Terms
SHPMF vs MCK, COR, CAH: 3-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Pharmaceuticals Holding Co 3-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's 3-Year EBITDA Growth Rate falls into.
Shanghai Pharmaceuticals Holding Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 2.00% mean?
Shanghai Pharmaceuticals Holding Co (SHPMF) has a 3-Year EBITDA Growth Rate of 2.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Shanghai Pharmaceuticals Holding Co and its competitors. This is 79% below median its historical median of 9.35. According to the industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #62 out of 105 companies in the Medical Distribution industry, placing it in the top 59%.
Is Shanghai Pharmaceuticals Holding Co's 3-Year EBITDA Growth Rate too high?
Shanghai Pharmaceuticals Holding Co's current 3-Year EBITDA Growth Rate of 2.00% is 79% below median its 10-year median of 9.35. The Medical Distribution industry median 3-Year EBITDA Growth Rate is 5.40. Shanghai Pharmaceuticals Holding Co's value of 2.00% is 63% below this industry median. Based on the distribution chart, Shanghai Pharmaceuticals Holding Co ranks #62 out of 105 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's 3-Year EBITDA Growth Rate compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #62 out of 105 companies for 3-Year EBITDA Growth Rate. This places Shanghai Pharmaceuticals Holding Co in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 5.40. Shanghai Pharmaceuticals Holding Co's value of 2.00% is 63% below this benchmark. While the company's 10-year median is 9.35 vs. the industry median of 5.40, Shanghai Pharmaceuticals Holding Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 5.40, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Pharmaceuticals Holding Co's current 3-Year EBITDA Growth Rate of 2.00% is 63% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Shanghai Pharmaceuticals Holding Co and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Pharmaceuticals Holding Co's current 3-Year EBITDA Growth Rate is 2.00%, which is 79% below median its own 10-year median of 9.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Shanghai Pharmaceuticals Holding Co (SHPMF) has a current 3-Year EBITDA Growth Rate of 2.00%. The stock's GF Value™ is $1.75, compared to a current price of $1.46 — trading 16.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 2.00%, which is 79% below median its 10-year median of 9.35 and 63% below the Medical Distribution industry median of 5.40. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (SHPMF), the current 3-Year EBITDA Growth Rate is 2.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Pharmaceuticals Holding Co (SHPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued.
The current stock price of $1.46 is trading 16.6% below its estimated GF Value™ of $1.75.
Key valuation signals for SHPMF:
3-Year EBITDA Growth Rate: 2.00% (79% below median its 10-year median of 9.35)
GF Value™: $1.75 vs. price of $1.46 (16.6% below fair value)
Industry Position: 63% below the Medical Distribution median (#62 of 105)
No single metric tells the full story. See the SHPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
79GF Score
Get the complete analysis for SHPMF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPMF has been successfully added to your 
